Eli Lilly & Co. (LLY) just plummeted to $134 and could be headed to $130 near-term. All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvementEli Lilly & Co. (LLY) just plummeted to $134 and could be headed to $130 near-term. All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvementEli Lilly & Co. (LLY) just plummeted to $134 and could be headed to $130 near-term. All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvementEli Lilly & Co. (LLY) just plummeted to $134 and could be headed to $130 near-term. All on news it ended a clinical trial of its antibody drug in hospitalized COVID patients after federal researchers said it produced no marked improvement
Here’s Why Eli Lilly & Co. Stock Gapped Lower
